Marco Gerlinger

List of Publications by Year
in descending order

53 papers	**12,255** citations	201674 **27** h-index	223800 **46** g-index
61 all docs	**61** docs citations	**61** times ranked	**20186** citing authors

#	Article	IF	Citations
1	Effect of perioperative FLOT *versus* ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. BJS Open, 2022, 6, .	1.7	3
2	Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. Cancer Research, 2022, 82, PR012-PR012.	0.9	0
3	Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. Cancer Research, 2022, 82, A002-A002.	0.9	0
4	Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes. , 2022, 39, .		7
5	Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. Journal of the National Cancer Institute, 2021, 113, 88-98.	6.3	15
6	Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough. Cancer Cell, 2021, 39, 16-18.	16.8	18
7	Identifying key questions in the ecology and evolution of cancer. Evolutionary Applications, 2021, 14, 877-892.	3.1	58
8	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. Nature Ecology and Evolution, 2021, 5, 1024-1032.	7.8	16
9	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. Frontiers in Oncology, 2020, 10, 1634.	2.8	2
10	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. European Journal of Cancer, 2020, 136, 99-106.	2.8	31
11	Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. Cancers, 2020, 12, 3736.	3.7	6
12	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nature Communications, 2020, 11, 139.	12.8	44
13	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell, 2019, 36, 35-50.e9.	16.8	179
14	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. Cancers, 2019, 11, 736.	3.7	15
15	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
16	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
17	Targeted drugs ramp up cancer mutability. Science, 2019, 366, 1452-1453.	12.6	13
18	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer, 2019, 18, 64-71.e1.	2.3	10

#	ARTICLE	IF	CITATIONS
19	Metastasis Seeding Cells: Lone Invaders or Mass Migrators?. Clinical Cancer Research, 2018, 24, 2032-2034.	7.0	7
20	Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. Critical Reviews in Oncology/Hematology, 2018, 122, 72-82.	4.4	40
21	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Clinical Chemistry, 2018, 64, 1626-1635.	3.2	46
22	Multiplexed single cell protein expression analysis in solid tumours using a miniaturised microfluidic assay. Convergent Science Physical Oncology, 2017, 3, 024003.	2.6	13
23	Classifying the evolutionary and ecological features of neoplasms. Nature Reviews Cancer, 2017, 17, 605-619.	28.4	303
24	Cancer (r)evolution. Nature Ecology and Evolution, 2017, 1, 1051-1052.	7.8	6
25	Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Medicine, 2016, 14, 185.	5.5	29
26	Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. Trends in Cancer, 2016, 2, 49-63.	7.4	222
27	Translating Seminoma Genomic Landscapes into Clinical Practice. European Urology, 2015, 68, 84-85.	1.9	0
28	Genetic Intratumor Heterogeneity. , 2015, , 571-593.		2
29	Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Current Opinion in Genetics and Development, 2015, 30, 1-6.	3.3	57
30	Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications. European Urology, 2015, 67, 729-737.	1.9	100
31	Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biology, 2014, 15, 433.	8.8	69
32	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. European Urology, 2014, 66, 936-948.	1.9	141
33	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics, 2014, 46, 225-233.	21.4	1,103
34	The promise of circulating tumor cell analysis in cancer management. Genome Biology, 2014, 15, 448.	8.8	47
35	Cancer: Evolution Within a Lifetime. Annual Review of Genetics, 2014, 48, 215-236.	7.6	196
36	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science, 2014, 346, 251-256.	12.6	962

#	ARTICLE	IF	CITATIONS
37	Computational optimisation of targeted DNA sequencing for cancer detection. Scientific Reports, 2013, 3, 3309.	3.3	20
38	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. Clinical Cancer Research, 2013, 19, 6924-6934.	7.0	62
39	Parallel evolution of tumour subclones mimics diversity between tumours. Journal of Pathology, 2013, 230, 356-364.	4.5	79
40	Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2013, 31, 971-972.	1.6	6
41	Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. Journal of Pathology, 2013, 231, 424-432.	4.5	93
42	Intratumor Heterogeneity: Seeing the Wood for the Trees. Science Translational Medicine, 2012, 4, 127ps10.	12.4	443
43	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New England Journal of Medicine, 2012, 366, 883-892.	27.0	6,769
44	Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. Journal of Pathology, 2012, 227, 146-156.	4.5	92
45	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer, 2010, 103, 1139-1143.	6.4	381
46	Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. Haematologica, 2010, 95, 1130-1135.	3.5	10
47	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer, 2010, 46, 2166-2177.	2.8	71
48	Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy. European Journal of Cancer, 2010, 46, 2913-2918.	2.8	17
49	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncology, The, 2010, 11, 358-365.	10.7	116
50	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine, 2010, 2, 53.	8.2	43
51	Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.. Blood, 2008, 112, 3251-3251.	1.4	0
52	Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. Journal of Immunology, 2006, 177, 8212-8218.	0.8	24
53	Egr-1 Induces the Expression of Its Corepressor Nab2 by Activation of the Nab2 Promoter Thereby Establishing a Negative Feedback Loop. Journal of Biological Chemistry, 2005, 280, 42785-42793.	3.4	83